A Dallas conference will examine how consumer-centered care is influencing healthcare across diagnostics, employer benefits, and other sectors.
MedCity News has announced INVEST Digital Health, scheduled for October 29 in Dallas. The event is positioned as a conversation on consumer-centered care across the healthcare ecosystem.
The announcement says the discussion will focus on the impact of consumer-centered care, spanning areas from diagnostics to employer benefits and beyond. The post does not list specific speakers or a detailed agenda, but it encourages registration for the event.
An Italian registry study reports high remission rates and steroid-sparing benefits for avacopan, offering real-world evidence as the drug faces safety and data-integrity questions.
A phase III trial found the investigational pan-amyloid tracer 124I-evuzamitide detected cardiac amyloidosis with high sensitivity and outperformed bone scintigraphy in early ATTR cases.
A physician's frustrating experience with an NIH biosketch form highlights how administrative redundancy in research and clinical work could be eased by AI.
Early-stage data suggest First Tracks' CD122-blocking drug ANB033 could become a new treatment option for celiac disease, which currently has no approved therapy.